Mymetics Corporation, a vaccine development company, made the acquisition of a preventive malaria vaccine from Pevion Biotech AG, a privately-held biotech company based in Switzerland.
The Pevion vaccine has successfully completed human clinical trial phases I and II in Switzerland and in the UK, respectively, with only two of four contemplated antigens. The clinical trials are being conducted in connection with the application for approval of this vaccine under the European Union regulations. A phase 1b clinical trial has been launched in Tanzania to extend the protocol to children and teenagers in a naturally endemic area. A new cycle of phase I and II clinical trials with all four antigens is scheduled thereafter.
The details can be read here.
No comments:
Post a Comment